Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Verisign, Inc. — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $57.04 (market cap $25.27B), while Verisign, Inc. trades at $305.64 (market cap $26.92B). The key difference: Royalty Pharma plc Class A Ordinary Shares and Verisign, Inc. are close in size by market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Verisign, Inc. for 123 Days on average.
| RPRX | VRSN | |
|---|---|---|
Market Cap | $25.27B | $26.92B |
Volume | 3,671,183 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $63.96 | $310.00 |
52-Week Low | $35.44 | $211.49 |
Typical Hold Time | 0 Days | 123 Days |
Enterprise Value | $32.50B | $28.23B |
Dividend Yield | 1.66% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VeriSign (VRSN) trades at $301.59, up 2.5% today, with a bullish technical signal and strong institutional buying. The company reported robust Q2 2026 earnings with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations. High profitability is evident with a net income margin near 50%, and cash flow trends are improving. Recent news includes a class-action antitrust lawsuit and insider selling by the CEO, but analyst consensus remains positive.
The outlook is supported by solid fundamentals and a consensus price target of $348, offering ~15% upside. Key risks include legal challenges from the antitrust suit and reliance on domain registration growth. Earnings momentum and institutional accumulation provide tailwinds, but investors should weigh litigation risks against the company's stable cash flows and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
